CEVAC IBIRD LYOPHILISATE FOR OCULONASAL SUSPENSION/ USE IN DRINKING WATER FOR CHICKENS

Authorised

- Infectious bronchitis virus, type 793/B, strain 1/96, Live

Product identification

Medicine name:
CEVAC IBIRD LYOPHILISATE FOR OCULONASAL SUSPENSION/ USE IN DRINKING WATER FOR CHICKENS

Active substance:
Infectious bronchitis virus, type 793/B, strain 1/96, Live

Target species:
Chicken (layer hen)
Chicken (broiler)

Route of administration:
Oculonasal use
Oral use

Product details

Active substance and strength:
Infectious bronchitis virus, type 793/B, strain 1/96, Live
2.80 log 10 50% embryo infective dose / 1.00 Dose

Pharmaceutical form:
Lyophilisate for oculonasal suspension/use in drinking water

Withdrawal period by route of administration:
Oculonasal use:

- **Chicken (layer hen)**
  - All relevant tissues. 0 day

- **Chicken (broiler)**
  - All relevant tissues. 0 day

Oral use:

- **Chicken (layer hen)**
  - All relevant tissues. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI01AD07

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Latvia

Package description:

Available only in Latvian
Available only in Latvian
Available only in Latvian
Available only in Latvian
Available only in Latvian
Available only in Latvian
Available only in Latvian
Available only in Latvian
Available only in Latvian
Available only in Latvian
Available only in Latvian
Available only in Latvian
Available only in Latvian
Available only in Latvian
Available only in Latvian

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Ceva-Phylaxia Zrt.

Marketing authorisation date:
3/10/2013

Manufacturing sites for batch release:
Ceva-Phylaxia Zrt.

Responsible authority:
Food And Veterinary Service

Authorisation number:
V/DCP/13/0031

Date of authorisation status change:
3/10/2013

Reference member state:
France

Procedure number:
FR/V/0245/001

Concerned member states:
Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland Germany Greece Hungary Ireland Italy Latvia Lithuania Luxembourg Malta Netherlands Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 14/04/2025
Download

eu-puar-frv0245001-mr-rpe774-en.pdf